Recent Updates
Recently added Catalysts

Refractory/ Relapsed Non-Hodgkin Lymphoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$610Muniverse median $1.20B
Allocated capital$203M$610M competing
Phase 3 or filed00 mid, 1 early
Pure plays0this indication only
Capital rank254/299crowding rank 256

Refractory/ Relapsed Non-Hodgkin Lymphoma is uncontested. Autolus Therapeutics (AUTL) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with AUTO1 in phase 1.

There is no public comparable to price it against. AUTL spreads its $610M market cap across 3 indications, so $203M of it is allocated here.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$203M of allocated capital sits in Refractory/ Relapsed Non-Hodgkin Lymphoma, ranking it 254th of 299 indications by the money committed to it.

Companies developing drugs for Refractory/ Relapsed Non-Hodgkin Lymphoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
AUTLAutolus TherapeuticsAUTO1Phase 12$610MNo3 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Refractory/ Relapsed Non-Hodgkin Lymphoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Refractory/ Relapsed Non-Hodgkin Lymphoma has one competitor and a median of $610M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Chronic Myeloid Leukemia1 company · $180M · median $1.6BUncontestedPhiladelphia Chromosome Positive Acute Lymphocytic Leukemia1 company · $180M · median $1.6BUncontestedLiposarcoma1 company · $180M · median $1.6BUncontestedAdvanced Multiple Myeloma1 company · $230M · median $460MUncontestedLeukemia1 company · $176M · median $176MUncontestedAdvanced Hepatocellular Carcinoma1 company · $175M · median $175MUncontestedRecurrent Acute Myeloid Leukemia1 company · $243M · median $970MUncontestedMetastatic Lung Cancer1 company · $162M · median $486MUncontested

Refractory/ Relapsed Non-Hodgkin Lymphoma pipeline questions

Which biotech companies are developing drugs for Refractory/ Relapsed Non-Hodgkin Lymphoma?

Autolus Therapeutics (AUTL, AUTO1, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Refractory/ Relapsed Non-Hodgkin Lymphoma.

How advanced is the Refractory/ Relapsed Non-Hodgkin Lymphoma pipeline?

Of the 1 clinical-stage programme in Refractory/ Relapsed Non-Hodgkin Lymphoma, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Refractory/ Relapsed Non-Hodgkin Lymphoma?

No. AUTL is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Refractory/ Relapsed Non-Hodgkin Lymphoma, which is why the indication is classified as uncontested.

When is the next Refractory/ Relapsed Non-Hodgkin Lymphoma catalyst?

The next dated catalyst in Refractory/ Relapsed Non-Hodgkin Lymphoma is AUTL on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map